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Abstract
Background: Asthma and COPD (chronic obstructive pulmonary disease) lead to persistent airway inflammation
and are associated with lung cancer. The objective of the study was to assess the relationship between inhaled
(ICS) and oral corticosteroid (OCS) use, and risk of lung squamous cell carcinoma (SqCC).
Methods: This study was a nested case–control study. Patients with newly diagnosed asthma or COPD between
2003 and 2010 were identified from the National Health Insurance Database. Cases were defined as patients
diagnosed with SqCC after enrollment. For each case, four control individuals who were randomly matched for sex
and age and date diagnosis of asthma or COPD were selected.
Results: From the 1,672,455 eligible participants, 793 patients with SqCC were matched with 3,172 controls. The
odds ratios (ORs) of SqCC in men who received high and low-dose ICS were 2.18 (95 %CI, 1.56–3.04) and 1.77
(1.22–2.57), respectively. Similarly, the ORs were 1.46 (95 %CI, 1.16–1.84) and 1.55 (95 %CI, 1.22–1.98) for men who
were placed on low and high dose OCS. However, there was no significant association between cumulative ICS
and/or OCS and risk of SqCC in women. Recent dose increase in corticosteriod was significantly associated with risk
of SqCC. Specifically, among men, the ORs for SqCC were 8.08 (95 %CI, 3.22–20.30) for high-dose ICS + OCS, 4.49
(95 % CI, 2.05–9.85) for high-dose ICS, and 3.54 (95 % CI, 2.50–5.01) for high-dose OCS treatments, respectively. The
OR for SqCC in women who received high-dose OCS was 6.72 (95 %CI, 2.69–16.81).
Conclusion: Corticosteroid use did not decrease SqCC in patients with asthma or COPD. Recent dose increase in
corticosteroids was associated with SqCC.
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Background
Squamous cell carcinoma (SqCC) accounts for approxi-
mately 20 % of all lung cancers in the United States [1].
It is the predominant histological type of lung cancer in
men [2]. Lung cancer has been linked with life expectancy
losses in Taiwan [3]. Chronic inflammation and frequent
pulmonary exacerbations may result in repeated injury
and repair which can lead to a high cell turnover, DNA
damage, malignant cell transformation, and ultimately,
development of lung cancer [4]. Asthma and chronic ob-
structive pulmonary disease (COPD) are chronic airway
inflammatory diseases commonly associated with lung
cancer [5, 6]. Severe airflow obstruction is an independent
risk factor for lung cancer [7, 8]. The prevalence of asthma
(11.9 %) and COPD (2.48 %) in Taiwan is high [9, 10].
Oral (OCS) and inhaled corticosteroid (ICS) have
reduced local and systemic inflammation among pa-
tients with asthma or COPD [11, 12]. However, stud-
ies to assess histologic type of lung cancer among
ICS and OCS users are limited. In this study, we in-
vestigated the association between corticosteroids
and SqCC.
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Data used in this study were obtained from 2003 to
2010 using the National Health Insurance Research
Database (NHIRD). Taiwan’s National Health Insurance
covers more than 99 % of the 23 million residents and
contains enrollment files, claims data, catastrophic ill-
ness files, and registry for treatments. The database is
one of the largest datasets described in most epidemio-
logical studies [13–15]. This study used multiple data-
bases: the NHIRD, Taiwan Cancer Registry Database
(TCRD), and National Death Registry Database (NDRD)
with permission of the Department of Statistics, Ministry
of Health and Welfare of Taiwan. The source data was
encrypted and the data extracted was anonymous. This
study was approved by the Institutional Review Board of
the Chung-Shan Medical University Hospital, Taiwan.
Study design
A nested case–control study was conducted to overcome
the time-varying nature of corticosteroid treatment. Ana-
lytic data included subjects aged ≥20 years with newly di-
agnosed asthma or COPD from 2003 to 2010. The date of
the first diagnosis of asthma or COPD was defined as the
initiation date. Excluded were individuals with incomplete
information on sex and registry data. Also excluded were
individuals diagnosed with lung cancer before 2002, initi-
ation date, or 2 years after the initiation date.
Identification of patients with lung cancer
The study began in 2003. Cases with newly diagnosed
lung cancer were followed until death, loss to follow-up,
or the study end in 2010. Lung cancer was identified
using the International Classification of Diseases, Ninth
Revision, Clinical Modification (ICD-9-CM) code 162.
The index date was defined as the date of first assign-
ment of the above ICD codes.
Case definition
The TCRD was used to confirm cell types of lung can-
cer. All major cancer care hospitals in Taiwan are obli-
gated to submit cancer type, initial tumor stages and
histology to Taiwan Cancer Registry funded by the Min-
istry of Health and Welfare [16]. Lung cancer was coded
by ICD-9-CM 162 or ICD 10 C34.0, C34.1, C34.2,
C34.3, C34.8, and C34.9. Morphological diagnoses were
made using the ninth revision of the International Clas-
sification of Diseases for Oncology, based on codes
80522, 80523, 80702, 80703, 80713, 80723, 80733,
80743, 80763, 80823, 80833, and 80843 for SqCC.
Control definition
For each case, up to four control individuals, who were
randomly matched for sex, age diagnosed with asthma
or COPD, and initiation date were selected without rep-
lication from individuals without lung cancer.
The NDRD, NHIRD, and TCRD were used to assess
the age at cancer onset, person-year follow-up, death
and survival time, and potentially unconfirmed cases di-
agnosed with cancer.
Inhaled and oral corticosteroid exposure
We identified patients who were prescribed OCS and ICS
between the initiation and index date. Data were collected
on prescription dates, prescribed daily dose, and the num-
ber of days supplied. In accordance with the Anatomic
Therapeutic Chemical classification of ICS drugs, beclo-
methasone, budesonide, fluticasone, and ciclesonide were
selected as the major drugs of interest, whether dispensed
alone or in combination with an inhaled β2 agonist. The
defined daily dose (DDD) recommended by the World
Health Organization is a unit for measuring a prescribed
amount of drug to standardize the comparison of drug
usage between different drugs [17]. All ICS were compared
using the following equation: total amount of a drug/DDD
of a drug = number of DDDs [18]. Cumulative DDD
(cDDD), which encompasses both dosage and duration of
exposure, was estimated as the sum of the dispensed
DDDs of any ICS and was used to correlate ICS use with
SqCC risk.
All OCS prescriptions were converted to hydrocorti-
sone equivalents (4 mg of hydrocortisone = 1 mg of
prednisolone = 5 mg of cortisone = 0.8 mg methylpred-
nisolone = 0.8 mg of triamcinolone = 0.4 mg of para-
methasone = 0.15 mg of betamethasone = 0.15 mg of
dexamethasone) [19].
An average quarter dose was calculated by dividing the
total number of milligrams of OCS or cDDDs of ICS by the
number of quarter prescribed during the assessment period.
Covariates
The diagnoses of pulmonary diseases and comorbidities
were confirmed by either 2 outpatient visits or one
hospitalization in one year. Baseline pulmonary diseases
and other comorbidities are listed as follows: asthma (ICD-
9-CM: 493), COPD (ICD-9-CM: 490, 491, 492, 494, and
496), pulmonary tuberculosis (ICD-9-CM: 010–012, and
137.0), pneumonia (ICD-9-CM: 486), chronic renal disease
(ICD-9-CM: 585 and 586), hyperlipidemia (ICD-9-CM:
272), and smoking-related cancers (ICD-9-CM: 140–150,
157, 160–161, and 189). Type 2 DM (ICD-9-CM: 250, ex-
cluding type I DM) is characterized by hyperinsulinemia in
the context of insulin resistance and an increased level of
circulating insulin-like growth factor 1 which are associated
with an increased risk of cancer [20]. Individuals with Type
1 DM were excluded because of exposure to lower levels of
exogenously administered insulin. As a proxy of COPD or
asthma severity, we assessed the number of outpatient and
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inpatient visits between the initiation and index date. How-
ever, information regarding lifestyle or behavior such as
smoking was not recorded in the NHIRD, hence preventing
direct adjustment of possible confounders.
Statistical analysis
Data analyses were made using SAS 9.3 software (SAS In-
stitute, Cary, NC). Chi-square and t tests were used to
compare baseline sociodemographic characteristics and
comorbidities between cases and controls. Conditional lo-
gistic regression was used to assess the association be-
tween corticosteroid use and SqCC. Low or high-dose
corticosteroid was defined by the median of corticosteroid
dose per quarter. Adjusted odd ratios (ORs) were pre-
sented with 95 % confidence intervals (CIs) and a P value
of less than 0.05 was considered statistical significance.
Results
We identified 2,384,046 individuals with first-time diagno-
sis of asthma or COPD from 2003 to 2010. The total
number of individuals excluded were as follows; <20 years
of age (n = 559,589), incomplete data on sex (n = 32,914)
and registration (n = 104,499), type 1 DM (n = 123), diag-
nosed with lung cancer before 2002 or initiation date, and
2 years after the initiation date (n = 14,466). The final en-
rolment included 1,672,455 individuals. A total of 4032
patients were identified with lung cancer, 793 of whom
were patients with SqCC.
Patients with SqCC and controls
The baseline characteristics of patients with SqCC (793)
and their controls (3172) are summarized in Table 1.
The sample size comprised 87.4 % of men. Cases had
comparatively low income, health care utilities, pneumo-
nia, pulmonary tuberculosis, smoking-related cancers,
and ICS and OCS use.
ICS and OCS and the risk of developing SqCC
Compared with non-ICS users (Model 1), the ORs for
SqCC in low and high-dose ICS were 2.09 (95 % CI,
1.52–2.88) and 1.88 (95 % CI, 1.32–2.66), respectively
(Table 2). Similarly, the ORs for SqCC in low and high-
dose OCS users were 1.48 (95 % CI, 1.20–1.83) and 1.54
(95 % CI, 1.22–1.93), respectively. Specifically, among
men (Model 2), the ORs for SqCC were 2.18 (95 % CI,
1.56–3.04) and 1.77 (1.22–2.57) in low and high-dose
ICS, and 1.46 (95 % CI, 1.16–1.84) and 1.55 (95 % CI,
1.22–1.98) in low and high-dose OCS users, respectively.
However, there was no increased risk of SqCC among
women who received ICS and OCS.
Risk of SqCC in patients with increased dose of
corticosteroids
In Table 3, recent dose increase in corticosteriods within
3 months prior to index date was significantly associated
with SqCC (Model 3). The adjusted ORs of SqCC were
8.01 (95 % CI, 3.38–19.01) in high-dose ICS + OCS, 4.14
(95 % CI, 1.98–8.66) in high-dose ICS, and 3.77 (95 % CI,
2.75–5.16) in high-dose OCS users. Specifically, among
men (Model 4), the ORs for SqCC were 8.08 (95 % CI,
3.22–20.30) in high-dose ICS +OCS, 4.49 (95 % CI, 2.05–
9.85) in high-dose ICS, and 3.54 (95 % CI, 2.50–5.01) in
high-dose OCS users. Among women (Model 4), the OR
for SqCC was 6.72 (95 % CI, 2.69–16.81) in high-dose OCS
users. There was no significant interactions between ICS,
OCS and SqCC (P = 0.234). The interactions between sex
and corticosteroids were also not significant (P = 0.764).
Discussion
Over the past decade, some studies have documented a
possible link between chronic inflammatory lung dis-
eases and lung cancer [5, 6]. Corticosteroids are used to
control persistent airway inflammation in patients with
COPD or asthma. However, the impact of corticoste-
roids on the specific types of lung cancer has not been
addressed. In this study, cumulative doses of OCS and
ICS were associated with SqCC in men. Our observation
also showed that SqCC was associated with a substantial
increase in steroid use in the preceding 3 months. How-
ever, it is far too short a time frame to be biologically
plausible that steroids are causing the cancer. High-dose
steroids are the standard treatment in acute exacerbation
of respiratory symptoms that may serve as risk factors
for SqCC.
Our results demonstrated that patients with SqCC had
significantly higher pneumonia, pulmonary tuberculosis,
and smoking-related cancers, but lower hyperlipidemia.
Because national databases do not contain detailed infor-
mation regarding smoking history, occupational exposures,
and other risk factors of lung cancer, other diseases (ex-
cluding COPD and asthma) may affect the risk of lung
SqCC. In a cohort study with 17,859,318 Taiwanese resi-
dents, Jian et al. evaluated gender disparities in pulmonary
diseases, comorbidities, and effects on SqCC [5]. A total of
6,637 cases of SqCC (male/female: 5877/760) were identi-
fied. Among men, TB and smoking-related cancers were
associated with increased risk of SqCC. However, hyperlip-
idemia was associated with a decreased risk. Among
women, TB, low income, type 2 DM, and smoking-related
cancers were attributed to increased risk of SqCC. In an-
other study involving 22,034 patients with pneumococcal
pneumonia, the hazard ratio (HR) of lung cancer was 4.24
(95 % CI, 3.96–4.55) [21]. These results are consistent with
our investigations.
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With effective treatment and control of allergens and irri-
tants, majority of patients with asthma or COPD have a
controlled disease though some patients can still be ex-
posed to frequent exacerbations [22, 23]. ICS therapy forms
the basis for treatment of asthma and COPD, improving
disease control and reducing exacerbations [24–26]. Acute
severe exacerbations require the addition of OCS to control
increased inflammation and respiratory symptoms [22]. Al-
though corticosteroids are powerful nonspecific anti-
inflammatory agents, they have little effect on biopsy
proven inflammation and did not change the rate of decline
of pulmonary function [23]. Airways hyper-responsiveness,
remodeling, and inflammation have persisted [27]. This in-
dicates that corticosteroids can’t prevent airway inflamma-
tion that may lead to lung carcinogenesis.
Few studies on the relationship between corticoste-
roids and lung cancer have yielded conflicting results.
Gundisch et al. found that glucocorticoids promoted
tumor cell proliferation in a pre-clinical mouse model of
lung carcinoma [28]. Budesonide produced 70 % inhib-
ition of lung tumor multiplicity and 94 % reduction of
total tumor in A/J mice [29]. Lee et al. analyzed new
adult users of ICS (9177 cases and 37,048 controls) using
the Korean national claims database [30]. Their study
Table 1 Baseline characteristics of controls and cases with lung
squamous cell carcinoma
Control (N = 3172) Case (N = 793) P-value
Sex (%) 1.000
Men 2772 (87.4) 693 (87.4)
Women 400 (12.6) 100 (12.6)
Low income (%) 0.028
No 3133 (98.8) 775 (97.7)
Yes 39 (1.2) 18 (2.3)
Urbanization (%) 0.012
Urban 1593 (50.2) 356 (44.9)
Suburban 1082 (34.1) 286 (36.1)
Rural 497 (15.7) 151 (19.0)
Age diagnosed with
asthma or COPD (year)
(mean ± sd)
71.6 ± 9.4 71.6 ± 9.4 1.000
Months between
initiation and index date
(mean ± sd)a
46.3 ± 16.3 46.3 ± 16.3 1.000




No. of outpatient visits
for asthma (%)
0–10 2925 (92.2) 698 (88.0) <0.001
>10 247 (7.8) 95 (12.0)
No. of hospitalization
for asthma (%)
0–2 3128 (98.6) 777 (98.0) 0.193
>2 44 (1.4) 16 (2.0)
No. of outpatient visits
for COPD (%)
0–10 2800 (88.3) 622 (78.4) <0.0001
>10 372 (11.7) 171 (21.6)
No. of hospitalization
for COPD (%)
0–2 2995 (94.4) 683 (86.1) <0.0001
>2 177 (5.6) 110(13.9)
Comorbidities (%)
Pneumonia 1179 (37.2) 483 (60.9) <0.0001
Pulmonary
tuberculosis
214 (6.7) 132(16.7) <0.0001
Chronic renal disease 302 (9.5) 90 (11.4) 0.123
Diabetes mellitus 1035 (32.6) 271 (34.2) 0.408
Hyperlipidemia 999 (31.5) 213 (26.9) 0.011
Smoking-related
cancers
63 (2.0) 40 (5.0) <0.0001
Table 1 Baseline characteristics of controls and cases with lung
squamous cell carcinoma (Continued)
Medication within 2-year




No use 2866 (90.4) 607 (76.5)
Lower dose (≦18.8) 156 (4.9) 95 (12.0)




No use 1955 (61.6) 338 (42.6)
Lower dose
(≦90.0 mg)
644 (20.3) 195 (24.6)
Higher dose
(>90.0 mg)




No use 1998 (63.0) 489 (61.7)
Lower dose
(≦3012.5)
574 (18.1) 165 (20.8)
Higher dose
(>3012.5)
600 (18.9) 139 (17.5)
cDDD cumulative defined daily dose, COPD chronic obstructive pulmonary
diseases, ICS inhaled corticosteroid, OCS oral corticosteroid, sd
standard deviation
aInitiation date was defined as the date asthma or COPD was diagnosed while
index date was defined as the date lung cancer when diagnosed
bLow and high dose medications were defined by the median dose
of medications
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findings showed that ICS use had a significant linear as-
sociation with a decreased lung cancer incidence. The
adjusted OR was 0.79 (95 % CI, 0.69–0.90). In a study
involving 10,474 United State veterans with COPD and a
median follow-up of 3.8 years, a dose-dependent de-
creased risk of lung cancer was associated with ICS (tri-
amcinolone >1,200 ug/day: adjusted HR, 0.39; 95 % CI,
0.16–0.96) [31]. However, after excluding participants
who were diagnosed with lung cancer in the first year
after enrollment, there was no significant reduction in
lung cancer. In a nested case–control study involving
patients (127 cases and 1470 controls) with newly diag-
nosed COPD who quitted smoking, and regular use of
ICS and bronchodilators, the HRs for lung cancer were
0.50 (95 % CI, 0.27–0.90) in ICS + long acting beta
agonist users and 0.64 (0.42–0.98) in ICS users com-
pared with short-acting bronchodilators users [32].
However, none of these trials has evaluated the rela-
tionship between corticosteroids and specific types of
lung cancer. Asthma and COPD have been closely asso-
ciated with SqCC [5]. In this study, a recent dose in-
crease in ICS and OCS is associated with SqCC. It is
possible that lung cancer may be found after exacerbation
of respiratory symptoms or treatment failure. An increased
lung cancer risk was strongest 2 years after asthma was di-
agnosed [33]. Lung cancer is hard to diagnose. Prior to re-
ferral, a third of patients consulted their general
practitioners three or more times with health problems re-
lated to lung cancer [34]. Diagnosis may be initially delayed
because of symptomatic masks resulting from exacerba-
tions of COPD and respiratory comorbidities [35, 36].
Prognosis of lung cancer is very poor. Longer diagnostic in-
tervals have been associated with increased cancer stage
and mortality [37]. In the presence of continuing or
Table 2 Risk of developing squamous cell carcinoma based on the cumulative dose of ICS and OCS
Mode 1 Model 2
All Male Female
OR (95 % CI) p-value OR (95 % CI) p-value OR (95 % CI) p-value
Medication within 2-year prior to index datea
ICS (cDDDs per quartier)
No use 1 - 1 - 1 -
Lower dose (≦18.8)b 2.09 (1.52–2.88) <.0001 2.18 (1.56–3.04) <.0001 1.16 (0.35–3.85) 0.812
Higher dose (>18.8) 1.88 (1.32–2.66) <0.001 1.77 (1.22–2.57) 0.003 2.96 (0.87–10.04) 0.082
OCS (Hydrocortisone equivalent/quarter)
No use 1 - 1 - 1 -
Lower dose (≦90.0 mg)b 1.48 (1.20–1.83) <0.001 1.46 (1.16–1.84) 0.001 1.59 (0.88–2.87) 0.124
Higher dose (>90.0 mg) 1.54 (1.22–1.93) <0.001 1.55 (1.22–1.98) <0.001 1.51 (0.75–3.04) 0.253
Each model was adjusted by low income, urbanization, health care utility, comorbidities and aspirin use
cDDD cumulative defined daily dose, CI confidence interval, ICS inhaled corticosteroid, OCS oral corticosteroid, OR odds ratio
aIndex date was defined as the date of lung cancer diagnosis
bLow and high-dose ICS and OCS were defined by the median of cumulative ICS and OCS dose (18.8 DDD / quarter and 90 mg
hydrocortisone/quarter, respectively).
Significant data are presented in bold font
Table 3 Adjusted risk for squamous cell carcinoma in patients with recent dose-increase in corticosteroids
Months before index datea Model 3 Model 4
−6 - -3 −3 – 0 All case Men Women
Control Case OR (95 % CI) OR (95 % CI) OR (95 % CI)
SqCC
ICSL + OCSL ICSL + OCSL 2589 475 1 1 1
ICSL + OCSL ICSL + OCSH 145 107 3.77 (2.75–5.16) 3.54 (2.50–5.01) 6.72 (2.69–16.81)
ICSL + OCSL ICSH + OCSL 20 18 4.14 (1.98–8.66) 4.49 (2.05–9.85) 3.65 (0.26–51.94)
ICSL + OCSL ICSH + OCSH 14 22 8.01 (3.38–19.01) 8.08 (3.22–20.30) 3.77 (0.24–60.39)
P for ICS × OCS interaction = 0.234
Each model was adjusted for low income, urbanization, health care utility, comorbidities, and aspirin use
Low and high-dose ICS and OCS were defined by the median of cumulative ICS and OCS dose (18.8 DDD/quarter and 90 mg hydrocortisone/quarter, respectively)
CI confidence interval, ICS inhaled corticosteroid, ICSH high cumulative dose of inhaled corticosteroid, ICSL low cumulative dose of inhaled corticosteroid, OCS oral
corticosteroid, OCSH high cumulative dose of oral corticosteroid, OCSL low cumulative dose of oral corticosteroid, OR odds ratio
aIndex date was defined as the date of lung cancer diagnosis
Significant data are presented in bold font
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changing respiratory symptoms, doctors should be aware
of the symptoms associated with lung cancer.
Our study results indicated no association between cu-
mulative dose of corticosteroids and SqCC in women. In
Taiwan, smoking is almost ten times more prevalent in
men (45.7 %) than women (4.8 %) [38]. This might have in-
fluenced the observed differences in risk of developing
SqCC between men and women. Except cigarette smoking,
cooking fumes had been associated with female SqCC [39].
Sex hormones play a role in gender-based differences such
as incidence, risk, histology, and pathogenesis of lung dis-
eases, and may either contribute to pathogenesis of disease
or serve as protective factors [40]. Besides, there were insuf-
ficient number of female patients to accurately analyze.
More studies ought to be conducted to investigate the asso-
ciation between corticosteroids and SqCC among women.
This study has several strengths. First, the sample size is
large with a long follow-up. It was based on nationwide da-
tabases, hence selection bias was possibly minimized. Sec-
ond, to enhance the reliability of temporal relationship
between corticosteroid use and SqCC, we excluded individ-
uals who were diagnosed with lung cancer before 2002 and
initiation date, or 2 years after initiation date. Nevertheless,
this study had some limitations. First, corticosteroid expos-
ure was assessed solely by refills recorded in the NHIRD,
not by whether the subjects actually used their medication.
Second, NHIRD, NDRD, and TCRD do not contain de-
tailed information regarding smoking history, radon expos-
ure, occupational exposures, diet preference, and family
history, all of which may be risk factors for lung cancer.
Conclusions
The use of corticosteroids in patients with asthma and
COPD was associated with lung SqCC, especially in men.
Recent dose-increase in corticosteroids was associated
with SqCC. Lung cancer screening is necessary when
treatment goals for asthma or COPD are not being met or
when patients are not responding to current therapy.
Abbreviation
cDDD: Cumulative defined daily dose; CI: Confidence interval; COPD: Chronic
obstructive pulmonary disease; DDD: Defined daily dose; DM: Diabetes
mellitus; HR: Hazard ratio; ICD-9-CM: International Classification of Diseases,
Ninth Revision, Clinical Modification code; ICS: Inhaled corticosteroid;
NDRD: National Death Registry Database; NHIRD: National Health Insurance
Research Database; OCS: Oral corticosteroid; OR: Odds ratio; SqCC: Lung
squamous cell carcinoma; TCRD: Taiwan Cancer Registry Database.
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